Retatrutide-RUO 10mg

Retatrutide 10mg is a synthetic, long-acting triple agonist peptide (also known as LY3437943) that activates the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This investigational 39-amino-acid peptide is derived from a GIP backbone with strategic modifications for balanced potency, enhanced stability, and extended pharmacokinetics. Key structural features include non-natural amino acid substitutions such as Aib (α-aminoisobutyric acid) at positions 2 and 20 for helix stabilization and resistance to degradation, α-methylleucine (aMeL) at position 13, and C-terminal serinamide amidation. It features acylation with a C20 fatty diacid moiety attached via a γ-Glu-(AEEA) linker at Lys¹⁷, enabling reversible albumin binding to prolong half-life (approximately 6 days or ~144 hours in relevant models) and support once-weekly administration in research contexts. Supplied as high-purity lyophilized powder (>98% purity, verified by HPLC and mass spectrometry), with molecular formula C₂₂₁H₃₄₂N₄₆O₆₈ and approximate molecular weight of 4731 Da. The core sequence incorporates elements like: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(αMeLeu)-Leu-Asp-Lys-[lipidated Lys]-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂.
Retatrutide is intended exclusively for in vitro research and scientific experimentation. It is commonly utilized in preclinical laboratory models to investigate multi-receptor agonism mechanisms, synergistic effects on metabolic signaling pathways, energy expenditure modulation (via GCGR), appetite regulation and satiety signaling (via GLP-1R and GIPR), glucose homeostasis, lipid metabolism, body weight dynamics, incretin/glucagon crosstalk, and related processes in cellular assays, tissue models, or animal systems exploring metabolic disorders, obesity models, and neuroendocrine regulation.